AstraZeneca Pharma India profit and loss

Latest FY26

Revenue: ₹2,276cr+32.6% on FY25
EBITDA: ₹262cr+3.2% on FY25
Net profit: ₹188cr+62.0% on FY25
EPS: ₹75.01+62.0% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,432	2,276	1,716	1,296	1,003	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	26.5	28.5	40.6	34.8	26.1
	2,459	2,304	1,757	1,330	1,029
	0.0	9.5	287	129	84.4
	1,746	1,859	1,009	499	324
	−214	−488	−333	−33.8	−48.9
	279	264	257	241	259
	5.7	4.5	1.5	1.2	0.6
	17.2	28.6	40.0	14.9	16.3
	391	369	242	275	219
	2,225	2,047	1,504	1,127	855
	230	262	254	184	165
	213	233	214	170	149
Profit
	233	257	253	203	174
	−5.1	−5.3	−96.8	16.4	−40.2
	228	252	156	220	134
	48.2	59.4	60.5	53.6	38.3
	10.4	5.3	−19.9	4.5	−3.5
	58.6	64.7	40.6	58.0	34.8
	170	188	116	162	99.3
	170	188	116	162	99.3
	−5.4	−4.4	−1.2	1.0	−2.6
	164	183	115	163	96.7
Per share
	₹67.85	₹75.01	₹46.30	₹64.60	₹39.72
	₹34.73	₹0.00	₹46.30	₹64.60	₹39.72
Other comprehensive income — detail
	−5.4	−4.4	−1.2	—	—
	−7.2	−5.9	−1.6	1.3	−3.5
	−1.8	−1.5	−0.4	—	—
	—	—	—	0.3	−0.9
Per share — as-filed variants
	₹67.85	₹75.01	₹46.30	₹64.60	₹39.72
	₹34.73	₹0.00	₹46.30	₹64.60	₹39.72
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	900	895	753	701	643
	37.0%	39.3%	43.9%	54.1%	64.1%
Adjusted (ex-exceptional items) — derived
	233	257	253	203	174
	−5.1	−5.3	−96.8	16.4	−40.2
	173	191	187	149	129
	₹69.37	₹76.57	₹74.96	₹59.77	₹51.64

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,237.00

AstraZeneca Pharma India Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,593 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,003.0	1,295.5	1,716.3	2,275.6	2,432.1
Other Income	26.1	34.8	40.6	28.5	26.5
Total Income	1,029.1	1,330.3	1,756.9	2,304.1	2,458.5
Expenses
+ Cost of Materials Consumed	84.4	129.0	287.1	9.5	0.0
+ Purchases of Stock-in-Trade	324.5	499.3	1,008.8	1,859.4	1,746.5
+ Changes in Inventories	-48.9	-33.8	-332.9	-488.4	-214.1
+ Employee Benefit Expense	259.1	241.5	257.4	264.4	279.1
+ Finance Costs	0.6	1.2	1.5	4.5	5.7
+ Depreciation & Amortisation	16.3	14.9	40.0	28.6	17.2
+ Other Expenses	218.8	275.1	241.9	368.6	390.8
Total Expenses	854.7	1,127.2	1,503.8	2,046.6	2,225.2
EBITDA	165.1	184.4	254.0	262.0	229.9
EBIT	148.9	169.5	214.0	233.5	212.6
Profit
PBT before Exceptional Items	174.3	203.1	253.2	257.5	233.4
+ Exceptional Items	-40.2	16.4	-96.8	-5.3	-5.1
Pretax Income	134.1	219.5	156.4	252.2	228.3
+ Current Tax	38.3	53.6	60.5	59.4	48.2
+ Deferred Tax	-3.5	4.5	-19.9	5.3	10.4
Tax Expense	34.8	58.0	40.6	64.7	58.6
Net Income	99.3	161.5	115.7	187.5	169.6
+ Net Income — Continuing Ops	99.3	161.5	115.7	187.5	169.6
+ Other Comprehensive Income	-2.6	1.0	-1.2	-4.4	-5.4
Total Comprehensive Income	96.7	162.5	114.6	183.1	164.3
Per Share
Basic EPS	39.72	64.60	46.30	75.01	67.85
Diluted EPS	39.72	64.60	46.30	0.00	34.73
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-1.2	-4.4	-5.4
+ Items NOT to be Reclassified to P&L	-3.5	1.3	-1.6	-5.9	-7.2
+ Tax on Items NOT to be Reclassified	—	—	-0.4	-1.5	-1.8
+ Tax on Items NOT to be Reclassified — alt tag	-0.9	0.3	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	39.72	64.60	46.30	75.01	67.85
Diluted EPS — Continuing Operations	39.72	64.60	46.30	0.00	34.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	643.0	701.0	753.3	895.0	899.7
Gross Margin %	64.11	54.11	43.89	39.33	36.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	174.3	203.1	253.2	257.5	233.4
− Exceptional Items (reconciliation)	-40.2	16.4	-96.8	-5.3	-5.1
Net Income Adj (tax-effected)	129.1	149.4	187.4	191.4	173.4
EPS Adj	51.64	59.77	74.96	76.57	69.37
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	2.00	—	—	—	—
Paid Up Equity Capital	5.0	5.0	5.0	5.0	5.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.